Robert Blum

“So, you know, MyCorso, Affie Campton, was engineered with certain properties in mind and was developed very much to elaborate on those properties. And I think those are playing well to what we hope ultimately proves competitive advantage in the marketplace.”

“And thanks for inviting us to participate in this back-to-school event.”

“As we reflect on the first half of 2026, I believe the progress that we've made demonstrates the strength of our execution and our strategic positioning as a maturing global growth enterprise.”

“So here in 2026, we're off to a great start, and things are continuing to go very well for cytokinetics.”

“So I'm joined today by two of our colleagues, Jeff and Dan. Jeff leads our sales organization, Dan leads clinical research for AFI Campton, Mike Corzo, and I think it's only fitting that the two of them be up here for the fact that those are the two key areas that I think are driving investor sentiment these days.”